Mineralys Therapeutics to Announce Q1 2024 Financial Results and Host Conference Call on May 9, 2024

Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company in the clinical stage, focuses on creating treatments for hypertension, chronic kidney disease (CKD), and other conditions linked to dysregulated aldosterone. On May 2, 2024, the company announced plans to release its financial results for the first quarter ending March 31, 2024. The announcement will take place before the financial markets open on Thursday, May 9, 2024.

Mineralys Therapeutics has scheduled a conference call at 8:30 a.m. ET on May 9 to discuss these financial results. Participants can join the call using the domestic number 1-888-886-7786 or the international number 1-416-764-8658, using the conference ID 93715931. There is also an option for instant telephone access via the Call me™ feature, which becomes active 15 minutes before the call starts. A live webcast of the conference call will be available on the Mineralys Therapeutics website, specifically on the “News & Events” page under the Investor Relations section.

Mineralys Therapeutics, headquartered in Radnor, Pennsylvania, was founded by Catalys Pacific. The company's primary focus is on developing lorundrostat, an oral and highly selective aldosterone synthase inhibitor. This proprietary product candidate targets cardiorenal conditions impacted by dysregulated aldosterone, such as hypertension and chronic kidney disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!